MDMA-assisted therapy shows promise for PTSD treatment and potential FDA approval

A recent Phase 3 clinical trial found MDMA combined with therapy significantly reduced PTSD symptoms compared to therapy alone.
Nearly 90% of PTSD patients who underwent MDMA-assisted therapy experienced meaningful improvements.
The results support previous research indicating MDMA's efficacy and safety for PTSD treatment.
The pharmaceutical sponsor plans to submit trial data to the FDA for potential approval of MDMA for PTSD as early as 2023.
If approved, MDMA would be the first psychedelic drug sanctioned by the FDA to treat a mental health condition.